- CPAS established nationwide preclinical AD cohort using plasma biomarkers and PET imaging to detect early Alzheimer's pathology across cognitive spectrum.
- Amyloid PET altered diagnosis and management; identified amyloid risk factors and expanded biomarkers to include synaptic and other PET markers.
- Future focus on disease modifying therapies and multi-omics integration to enable personalised medicine and improve therapeutic outcomes in China and globally.
Mol Psychiatry. 2026 Aug 1. doi: 10.1038/s41380-026-03797-9. Online ahead of print.
ABSTRACT
This review delves into the advancements in Alzheimer’s Disease (AD) research in China, focusing on insights, innovations, and future directions derived from the Chinese Preclinical Alzheimer’s Disease Study (CPAS). With an aging population, AD prevalence has risen, increasing societal and economic burdens. CPAS, initiated in 2019, aims to identify early Alzheimer’s pathology using plasma biomarkers and PET imaging. The study includes participants across the cognitive spectrum, including cognitively unimpaired individuals, patients with mild cognitive impairment (MCI), and patients with dementia, undergoing comprehensive assessments. Key findings include the impact of Aβ-PET on diagnosis and management, risk factors for amyloid pathology, and the expansion of biomarkers to include synaptic and other PET imaging markers. Future directions involve exploring disease-modifying therapies and applying multi-omics approaches to enhance the understanding and treatment of AD. These efforts are crucial for advancing personalized medicine and improving therapeutic outcomes in China and globally.
PMID:42542440 | DOI:10.1038/s41380-026-03797-9
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
